

ExonHit updates its shareholders regarding the extraordinary shareholders' meeting about RedPath acquisition

Paris, France – June 23, 2010 – Due to the turnout of votes to date, ExonHit Therapeutics informs its shareholders that the extraordinary shareholders' meeting convened on Monday, June 28, 2010 to vote on the acquisition of RedPath Integrated Pathology, is unlikely to deliberate on that date for lack of quorum. In such hypothesis, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France

All documents and information about the meeting may be found on the Company's website: <http://www.exonhit.com> (section "Investors"/"general meeting").

As a reminder, ExonHit Therapeutics informed its shareholders on June 18, 2010 that Highmark Medical Services Inc. (a Medicare regional antenna) announced its intention to revisit reimbursement decision of PathFinderTG® – Pancreatic cancer, contingent upon a complementary assessment of the clinical utility of the product. RedPath is currently assembling a dossier demonstrating such utility, by gathering clinical data of trials conducted by third parties since the 2007 evaluation of the test performed by Highmark, which decided to initiate local coverage. This dossier will be supported by the testimonies of clinicians and patients, and will be submitted on July 9, 2010. Highmark final decision regarding product coverage will begin applying on September 29, 2010.

RedPath acquisition remains a strategic goal for ExonHit Therapeutics and ExonHit Therapeutics is monitoring the situation in the best interest of the Company and of its shareholders. ExonHit Therapeutics will keep its shareholders regularly informed of the evolution of the situation.

About RedPath Integrated Pathology, Inc.

ExonHit Therapeutics announced on April 26, 2010 the signature of a binding agreement for the acquisition of RedPath Integrated Pathology, Inc., a privately held US molecular diagnostic company, focused on cancer (2009 turnover: USD 5.4 million). According to the terms of this combination agreement, and upon approval of ExonHit's shareholders at an extraordinary shareholders' meeting, ExonHit will pay an upfront of USD 12.5 million in cash and USD 10 million in stock at the closing of the transaction. Starting in 2012, RedPath's current shareholders may receive subsequent additional payments of up to USD 9.5 million, depending on the achievement of sales targets. The transaction, if approved, is expected to close by mid-July 2010.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood based diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com